logo
Wintrust Financial Corp (WTFC) Q4 2024 Earnings Call Highlights: Record Net Income and Balanced ...

Wintrust Financial Corp (WTFC) Q4 2024 Earnings Call Highlights: Record Net Income and Balanced ...

Yahoo21-04-2025

Full-Year Net Income: $695 million, up over 11.5% from 2023.
Fourth-Quarter Net Income: Approximately $185.4 million.
Net Interest Income: Increased by $22.6 million from the prior quarter.
Net Interest Margin: 3.51%, stable compared to the prior quarter.
Loan Growth: $1 billion for the quarter, 8% annualized.
Deposit Growth: $1.1 billion for the quarter, 9% annualized.
Total Assets: Grew approximately $1.1 billion to $64.9 billion.
Provision for Credit Losses: $17 million in the fourth quarter, down from $22.3 million in the prior quarter.
Non-Interest Income: Stable at approximately $113 million for the quarter.
Non-Interest Expenses: Totaled $368.5 million, up approximately $7.9 million from the third quarter.
Non-Performing Loans: Decreased from 38 basis points to 36 basis points of total loans.
Charge-Offs: $15.9 million or 13 basis points, down from $26.7 million or 23 basis points in Q3.
CRE Office Exposure: $1.7 billion, 12.8% of total CRE portfolio, 3.5% of total loan portfolio.
Warning! GuruFocus has detected 4 Warning Sign with WTFC.
Release Date: January 22, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Wintrust Financial Corp (NASDAQ:WTFC) reported record net income of $695 million for 2024, marking an 11.5% increase from 2023.
The company achieved balanced growth in loans and deposits, each increasing by approximately $1 billion in the fourth quarter.
Net interest income rose by 4.5% quarter over quarter and nearly 12% compared to the previous year's fourth quarter.
Non-performing loans and charge-offs decreased relative to the previous quarter, indicating improved credit performance.
WTFC's treasury management and wealth businesses continued to show steady growth, contributing to noninterest revenue expansion.
The mortgage business remains relatively insignificant in terms of financial impact, with current activity muted.
Acquisition-related costs and security losses were noted as uncommon items impacting the quarter's financials.
There is increased competitive pressure in the market, particularly in the commercial real estate sector, affecting pricing and structure.
Noninterest expenses increased by $7.9 million from the third quarter, partly due to acquisition-related costs and increased software expenses.
The company faces challenges from a prolonged higher interest rate environment, particularly affecting commercial real estate valuations.
Q: Can you discuss the competitive landscape and your expectations for loan growth in 2025? A: Richard Murphy, Vice Chairman and Chief Lending Officer, noted that while Wintrust has grown when others have not, there is increased competition, particularly in commercial real estate (CRE). The company remains committed to not chasing deals that don't meet their standards. They maintain their guidance for mid- to high single-digit loan growth, despite some headwinds.
Q: What is your outlook for the mortgage business given current interest rates? A: Timothy Crane, President and CEO, mentioned that while mortgage activity remains muted, a rate near 6% could stimulate activity. Inventory is improving, and they are hopeful for a spring pickup, but current rates around 7% are less favorable.
Q: How are you approaching expense management in 2025? A: David Dykstra, Vice Chairman and COO, emphasized that expense management is a good practice, and they plan to grow expenses at a mid-single-digit rate, which is less than their expected loan growth. They are investing in digital products and infrastructure to support growth.
Q: What is your strategy regarding mergers and acquisitions (M&A) and capital priorities? A: Timothy Crane stated that while they field calls and see increased enthusiasm post-election, they remain disciplined. They focus on organic growth and geographic expansion, such as in Rockford, Illinois. Capital is primarily used to support growth, and they are not currently considering buybacks.
Q: Can you provide insights into your deposit repricing and margin outlook? A: David Dykstra explained that the interest-bearing deposit beta is around 65-67%, with incremental deposits coming in at 3-4%. They expect the net interest margin to remain around 3.5% throughout 2025, supported by matched loan and deposit growth.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Insurance tech firm Slide targets over $2 billion valuation in Nasdaq IPO
Insurance tech firm Slide targets over $2 billion valuation in Nasdaq IPO

Yahoo

time33 minutes ago

  • Yahoo

Insurance tech firm Slide targets over $2 billion valuation in Nasdaq IPO

-- Insurance technology company Slide is pursuing a valuation of up to $2.12 billion in its upcoming initial public offering (IPO) on the Nasdaq exchange. The company disclosed the target in a filing on Monday. In collaboration with some of its existing stakeholders, Slide is aiming to raise up to $340 million from the IPO. This move is in line with a recent trend of successful stock market debuts by insurance firms. Barclays and Morgan Stanley have been named as the lead underwriters for the listing. The shares of the company are anticipated to begin trading on the Nasdaq exchange under the ticker symbol "SLDE". Related articles Insurance tech firm Slide targets over $2 billion valuation in Nasdaq IPO Morgan Stanley downgrades Lululemon on weak US growth outlook Tesla shares slip after double downgrade amid Trump feud fallout Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Sitio Royalties downgraded after Viper Energy agrees to acquire co for $19.41/shr
Sitio Royalties downgraded after Viper Energy agrees to acquire co for $19.41/shr

Yahoo

time33 minutes ago

  • Yahoo

Sitio Royalties downgraded after Viper Energy agrees to acquire co for $19.41/shr

-- Texas Capital has downgraded Sitio Royalties Corp (NYSE:STR) to Hold from Buy after the company agreed to be acquired by Viper Energy (NASDAQ:VNOM) in an all-stock transaction valued at $19.41 per share. The downgrade comes as analysts no longer see material upside following the announced deal, which values Sitio at about $4.1 billion. Texas Capital also cut its price target on Sitio to $20 from $29, in line with the proposed merger terms. 'We are positive on the transaction,' analysts wrote, citing strategic fit, increased scale, low leverage, and an attractive base dividend breakeven below $20 per barrel WTI. 'The combination creates a must-own Minerals company.' Texas Capital does not expect any competing bids given the lack of well-capitalized public rivals in the space. Viper Energy said the deal will make it the largest public mineral and royalty company in the U.S., with positions in the Permian and other key basins. The transaction is expected to close in the second half of 2025, subject to shareholder and regulatory approvals. Related articles Sitio Royalties downgraded after Viper Energy agrees to acquire co for $19.41/shr Tesla shares gain as Trump wishes Musk 'well' GFL weighs sale in infrastructure arm valued at C$5 billion - Bloomberg Sign in to access your portfolio

Anteris Appoints David Roberts and Gregory Moss to its Board of Directors
Anteris Appoints David Roberts and Gregory Moss to its Board of Directors

Yahoo

timean hour ago

  • Yahoo

Anteris Appoints David Roberts and Gregory Moss to its Board of Directors

New Directors Bring Extensive NASDAQ Expertise Across Legal, Operational and Corporate Leadership Capacities MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the appointments of Mr. David Roberts and Mr. Gregory Moss to its Board of Directors. The Company also announced the resignation of Dr. Wenyi Gu from the Board upon completion of his term as an Australia-based non-executive director. 'On behalf of the management team and Board, I am delighted to welcome David and Gregory to the Company' commented John Seaberg, Chairman of Anteris. 'On the heels of our Q4 2024 listing onto NASDAQ, and as we ramp-up activities to launch the DurAVR® THV global, pivotal clinical trial (the "PARADIGM Trial"), we are excited to enhance the leadership team with two highly accomplished, U.S. based, healthcare executives as the company transitions to its next phase of growth. I also wish to extend gratitude to Dr. Gu for his commitment and contributions to the company over the course of his tenure as a member of the Board and wish him well on his future endeavors.' Mr. David Roberts is currently President of LeMaitre Vascular, Inc. (NASDAQ: LMAT), a position he has held since 2007. He joined LeMaitre in 1997 as Vice President of Business Development and was promoted to Chief Financial Officer in 2000. Prior to LeMaitre, Mr. Roberts served as Vice President of Development for BUCA, Inc. from 1994 to 1997, and prior to that as Associate of HarbourVest Partners from 1992 to 1994. Mr. Roberts received a Bachelor of Arts in Business Economics and History from Brown University and a Master of Business Administration from the Stanford University Graduate School of Business. Mr. Roberts serves as a director of LeMaitre Vascular, Inc., Lexington Medical, Inc. and Parasole Restaurant Holdings, Inc. Mr. Gregory Moss serves as Chief Business and Legal Officer, as well as Corporate Secretary and Chief Compliance Officer of Evommune, Inc. Prior to Evommune, Mr. Moss served as Executive Vice President, General Counsel, and Corporate Secretary, Chief Compliance Officer at Kadmon, a Sanofi Company, where he led legal, compliance, and business development operations, culminating in Kadmon's $1.9 billion acquisition in 2021. Prior to joining Kadmon in 2012, Mr. Moss served as a solicitor in the corporate risk department of a large Australian law firm and as an associate at a boutique law firm and hedge fund in New York, where he focused on complex litigation and event-driven outcomes. Mr. Moss currently serves on the board of Vitls, Inc. Mr. Moss earned a BA and an LLB from Macquarie University, Australia, and is a member of the Bar Associations of New York, USA, and New South Wales, Australia, with admissions before the Supreme Court of the United States of America; Southern District of New York; Supreme Court of New South Wales, Australia; and High Court of Australia. Mr. Roberts and Mr. Moss will help guide Anteris through its next phase of growth, with the upcoming global pivotal PARADIGM study in 3Q2025 towards the ultimate U.S. and EMA licensure of the DurAVR® THV for patients with aortic stenosis. About Anteris Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients. Anteris' lead product, the DurAVR® Transcatheter Heart Valve (THV), was designed in partnership with the world's leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR® THV is made using a single piece of molded ADAPT® tissue, Anteris' patented anti-calcification tissue technology. ADAPT® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR® THV System is comprised of the DurAVR® valve, the ADAPT® tissue, and the balloon-expandable ComASUR® Delivery System. For more information: Investor Relations investor@ OrmsbyAnteris Technologies Global Corp.+61 1300 550 310 | +61 7 3152 3200 Investor Relations (US)mchatterjee@ Chatterjee, Life Science Group+1 917 330 4269WebsiteXFacebookLinkedIn in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store